- Home
- CAPR vs MCR Comparison
CAPR vs MCR Comparison
Compare CAPR & MCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- MCR
- Stock Information
- Founded
- CAPR 2005
- MCR 1989
- Country
- CAPR United States
- MCR United States
- Employees
- CAPR N/A
- MCR N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- MCR Trusts Except Educational Religious and Charitable
- Sector
- CAPR Health Care
- MCR Finance
- Exchange
- CAPR Nasdaq
- MCR Nasdaq
- Market Cap
- CAPR 324.6M
- MCR 265.5M
- IPO Year
- CAPR N/A
- MCR N/A
- Fundamental
- Price
- CAPR $7.62
- MCR $6.45
- Analyst Decision
- CAPR Strong Buy
- MCR
- Analyst Count
- CAPR 7
- MCR 0
- Target Price
- CAPR $24.71
- MCR N/A
- AVG Volume (30 Days)
- CAPR 1.4M
- MCR 66.7K
- Earning Date
- CAPR 11-12-2025
- MCR 01-01-0001
- Dividend Yield
- CAPR N/A
- MCR 8.52%
- EPS Growth
- CAPR N/A
- MCR N/A
- EPS
- CAPR N/A
- MCR 0.38
- Revenue
- CAPR $13,392,150.00
- MCR N/A
- Revenue This Year
- CAPR N/A
- MCR N/A
- Revenue Next Year
- CAPR $7,894.07
- MCR N/A
- P/E Ratio
- CAPR N/A
- MCR $16.61
- Revenue Growth
- CAPR N/A
- MCR N/A
- 52 Week Low
- CAPR $5.68
- MCR $5.63
- 52 Week High
- CAPR $23.40
- MCR $6.70
- Technical
- Relative Strength Index (RSI)
- CAPR 54.02
- MCR 50.40
- Support Level
- CAPR $7.11
- MCR $6.36
- Resistance Level
- CAPR $8.06
- MCR $6.50
- Average True Range (ATR)
- CAPR 0.51
- MCR 0.07
- MACD
- CAPR 0.16
- MCR -0.01
- Stochastic Oscillator
- CAPR 72.64
- MCR 40.11
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About MCR MFS Charter Income Trust
MFS Charter Income Trust is a United States-based closed-end fund. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests the assets in Debt Instruments, Corporate Bonds, U.S. Government Securities, Foreign Government Securities, Securitized Instruments, Derivatives, Principal Risks, Debt Management Risk, Investment Selection Risk, Interest Rate Risk, Credit Risk, Foreign Risks, Emerging Markets Risk, Currency Risk, Leveraging Risk, Operational and Cybersecurity Risk, Active and Frequent Trading, and etc of different market countries.